Back to Crohns Disease And Colitis
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02539368

NCT02539368
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You were at least 12 years old when you were first diagnosed with Crohn's disease (CD) or ulcerative colitis (UC), and you are at least 18 years old at the time of joining the study.
  • Your doctor has prescribed you either CT-P13 (a biosimilar infliximab) or Remicade (infliximab) to treat your Crohn's disease or ulcerative colitis, following standard prescribing guidelines.
  • You may still be eligible if you have had a stoma, bowel surgery, or a pouch procedure.

Who may not be able to join:

  • You have any medical reasons why you should not take CT-P13 or Remicade, based on the official prescribing guidelines (confirm with trial site).
  • You have a known allergy or serious reaction to infliximab, any of its ingredients, or similar proteins derived from mice — including any severe reactions during a previous infusion.
  • You have previously tried Remicade or CT-P13 and it did not work for you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
22 April 2015
Est. completion
31 October 2018

Where this trial is recruiting

🇧🇪 Belgium 🇨🇿 Czechia 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇹 Portugal 🇸🇰 Slovakia 🇪🇸 Spain 🇬🇧 United Kingdom

Primary endpoints

Disease Characteristics of Participants: Disease Duration; Number of Participants Who Switched Treatment; Reasons for Switching Treatment by Participants; Total Dose of Infusion Received; Number of Participants by Frequency of Infusion Received; Number of Participants Who Had Change in Infusion Dose; Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change; Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC); Number of Participants With Treatment-Emergent Adverse Event (AEs), Se...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov